2 weeks ago
19
Keith Noonan, The Motley Fool
Sun, August 9, 2026 astatine 11:48 AM CDT 3 min read
Usana Health Sciences (NYSE: USNA) banal saw a immense valuation contraction this week successful effect to disappointing second-quarter results. The company's stock terms declined 30% crossed the stretch. Meanwhile, the S&P 500 roseate 3.6%, and the Nasdaq Composite gained 5.2%.
Usana published its 2nd 4th results connected Aug. 4, and some income and net for the play came successful importantly worse than the mean expert estimates. In summation to the anemic Q2 print, the institution besides issued caller guardant guidance that disappointed the market.
Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »
Usana's Q2 results suggest the concern is struggling
In the 2nd quarter, Usana recorded non-GAAP (adjusted) net of $0.07 per stock connected income of astir $223 million. The company's adjusted nett per stock came successful $0.50 beneath the level called for by the mean expert estimate, and gross for the play was astir $12 cardinal little than the mean forecast. In summation to Q2 net that came successful acold beneath Wall Street's forecast and a meaningful income miss, the company's Q2 study besides arrived with disappointing guardant guidance.
What's adjacent for Usana?
With its Q2 report, Usana announced that it would beryllium taking a $29 cardinal goodwill impairment complaint connected the worth of its Hiya business. As a result, the institution present expects to grounds a nonaccomplishment of astir $11 cardinal this twelvemonth -- down from erstwhile guidance for a nett betwixt $20 cardinal and $27 million. The institution besides lowered its full-year income target.
While the company's halfway nutrition conception has shown immoderate signs of stabilization, that was offset by weaker results for its Hiya and Rise segments. As a result, the institution lowered its full-year income guidance from betwixt $925 cardinal and $1 cardinal to $910 million. With net coming successful acold weaker than expected successful the 2nd 4th and guardant guidance suggesting that headwinds volition persist successful the adjacent term, Usana banal could stay nether unit until the institution tin show meaningful signs that show is rebounding.
Should you bargain banal successful USANA Health Sciences close now?
Before you bargain banal in USANA Health Sciences, see this:
The Motley Fool Stock Advisor analyst squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and USANA Health Sciences wasn't 1 of them. The 10 stocks that made the chopped are built for semipermanent maturation and could nutrient monster returns successful the coming years.
English (CA) · 
English (US) · 
Spanish (MX) ·